复发/难治性皮肤T细胞淋巴瘤的非化疗药物新选择

doi:10.35541/cjd.20210850

中华皮肤科杂志 ›› 2023, Vol. 56 ›› Issue (12): 1170-1173.doi: 10.35541/cjd.20210850

复发/难治性皮肤T细胞淋巴瘤的非化疗药物新选择

王冠钰王艺萌李薇薇张春雷

北京大学第三医院皮肤科，北京 100191

收稿日期:2021-11-24 修回日期:2022-07-18 发布日期:2023-12-05
通讯作者: 张春雷 E-mail:zhangchunleius@163.com
基金资助:
国家自然科学基金（81972560）；北京市自然科学基金（7202231）；北京大学医学部青年培育项目（BMU2020PYB023）

Novel non-chemotherapeutic treatment options for relapsed/refractory cutaneous T-cell lymphomas

Wang Guanyu, Wang Yimeng, Li Weiwei, Zhang Chunlei

Department of Dermatology, Peking University Third Hospital, Beijing 100191, China

Received:2021-11-24 Revised:2022-07-18 Published:2023-12-05
Contact: Zhang Chunlei E-mail:zhangchunleius@163.com
Supported by:
National Natural Science Foundation of China （81972560）; Beijing Natural Science Foundation （7202231）; The Fund for Fostering Young Scholars of Peking University Health Science Center of China （BMU2020PYB023）

摘要/Abstract

摘要： 【摘要】随着对皮肤T细胞淋巴瘤研究的不断深入，传统靶向药物、免疫检查点抑制剂、组蛋白去乙酰化酶抑制剂以及异基因造血干细胞移植等各种治疗手段不断出现，均在临床试验中显示出良好的疗效及安全性。本文综述近年复发/难治性皮肤T细胞淋巴瘤非化疗药物的相关研究进展。

关键词: 淋巴瘤, T细胞, 皮肤, 分子靶向治疗, 免疫检查点抑制剂, 异基因造血干细胞治疗, 基于嵌合抗原受体修饰的T细胞疗法

Abstract: 【Abstract】 With the advances in research on cutaneous T cell lymphomas （CTCL）, some new strategies, such as traditional targeted drugs, immune checkpoint inhibitors, histone deacetylase inhibitors and allogeneic hematopoietic stem cell transplantation, have emerged and shown favorable efficacy and safety in clinical trials. This review summarizes recent research progress in non-chemotherapeutic drugs for relapsed/refractory cutaneous T-cell lymphomas.

Key words: Lymphoma, T-cell, cutaneous, Molecular targeted therapy, Immune checkpoint inhibitor, Allogeneic hematopoietic stem cell transplantation, CAR T-cell therapy

王冠钰王艺萌李薇薇张春雷. 复发/难治性皮肤T细胞淋巴瘤的非化疗药物新选择[J]. 中华皮肤科杂志, 2023,56(12):1170-1173. doi:10.35541/cjd.20210850

Wang Guanyu, Wang Yimeng, Li Weiwei, Zhang Chunlei. Novel non-chemotherapeutic treatment options for relapsed/refractory cutaneous T-cell lymphomas[J]. Chinese Journal of Dermatology, 2023, 56(12): 1170-1173.doi:10.35541/cjd.20210850

参考文献 28

［1］	Hristov AC, Tejasvi T, A Wilcox R. Cutaneous T⁃cell lymphomas: 2021 update on diagnosis, risk⁃stratification, and management［J］. Am J Hematol, 2021,96（10）:1313⁃1328. doi: 10.1002/ajh. 26299.
［2］	Kim YH, Bagot M, Pinter⁃Brown L, et al. Mogamulizumab versus vorinostat in previously treated cutaneous T⁃cell lymphoma （MAVORIC）: an international, open⁃label, randomised, controlled phase 3 trial［J］. Lancet Oncol, 2018,19（9）:1192⁃1204. doi: 10. 1016/S1470⁃2045（18）30379⁃6.
［3］	Chen L, Carson KR, Staser KW, et al. Mogamulizumab⁃associated cutaneous granulomatous drug eruption mimicking mycosis fungoides but possibly indicating durable clinical response［J］. JAMA Dermatol, 2019,155（8）:968⁃971. doi: 10.1001/jamadermatol.2019.0369.
［4］	Prince HM, Kim YH, Horwitz SM, et al. Brentuximab vedotin or physician′s choice in CD30⁃positive cutaneous T⁃cell lymphoma （ALCANZA）: an international, open⁃label, randomised, phase 3, multicentre trial［J］. Lancet, 2017,390（10094）:555⁃566. doi: 10.1016/S0140⁃6736（17）31266⁃7.
［5］	Papadavid E, Pappa V, Kapniari E, et al. Real life data on advanced cutaneous T cell lymphoma patients treated with brentuximab vedotin: results from a multicenter European EORTC study ［J］. European Journal of Cancer, 2019,119:S34⁃S35. doi: 10.1016/S0959⁃8049（19）30604⁃5.
［6］	Bagot M, Porcu P, Marie⁃Cardine A, et al. IPH4102, a first⁃in⁃class anti⁃KIR3DL2 monoclonal antibody, in patients with relapsed or refractory cutaneous T⁃cell lymphoma: an international, first⁃in⁃human, open⁃label, phase 1 trial［J］. Lancet Oncol, 2019,20（8）:1160⁃1170. doi: 10.1016/S1470⁃2045（19）30320⁃1.
［7］	Bagot M, Kim Y, Zinzani P L, et al. Lacutamab in patients （PTS） with advanced mycosis fungoides （MF） according to KIR3DL2 expression: early results from the tellomak phase 2 trial ［J］. Hematological oncology, 2021,39（Suppl 2）:97⁃98. doi: 10.1002/hon.2879.
［8］	Sawas A, Elgedawe H, Vlad G, et al. Clinical and biological evaluation of the novel CD30/CD16A tetravalent bispecific antibody （AFM13） in relapsed or refractory CD30⁃positive lymphoma with cutaneous presentation: a biomarker phase Ib/IIa study （NCT03192202）［J］. Blood, 2019,37（Suppl 2）:314⁃316.doi:10.1182/blood⁃2018⁃99⁃115269.
［9］	Pérez C, Mondéjar R, García⁃Díaz N, et al. Advanced⁃stage mycosis fungoides: role of the signal transducer and activator of transcription 3, nuclear factor⁃κB and nuclear factor of activated T cells pathways［J］. Br J Dermatol, 2020,182（1）:147⁃155. doi: 10.1111/bjd.18098.
［10］	Moskowitz A J, Ghione P, Jacobsen E D, et al. Final results of a phase II biomarker⁃driven study of ruxolitinib in relapsed and refractory T⁃cell lymphoma ［J］. Blood, 2019,134:4019. doi:10.1182/blood⁃2019⁃125017.
［11］	Karagianni F, Piperi C, Mpakou V, et al. Ruxolitinib with resminostat exert synergistic antitumor effects in Cutaneous T⁃cell Lymphoma［J/OL］. PLoS One, 2021,16（3）:e0248298. doi: 10. 1371/journal.pone.0248298.
［12］	Khodadoust MS, Rook AH, Porcu P, et al. Pembrolizumab in relapsed and refractory mycosis fungoides and Sézary syndrome: a multicenter phase II study［J］. J Clin Oncol, 2020,38（1）:20⁃28. doi: 10.1200/JCO.19.01056.
［13］	Shin J, Ho Lee D, Lee WJ, et al. Mycosis fungoides development after combined immune checkpoint blockade therapy in a patient with malignant melanoma: a case report［J］. Melanoma Res, 2020,30（5）:515⁃518. doi: 10.1097/CMR.0000000000000664.
［14］	Lesokhin AM, Ansell SM, Armand P, et al. Nivolumab in patients with relapsed or refractory hematologic malignancy: preliminary results of a phase Ib study［J］. J Clin Oncol, 2016,34（23）:2698⁃2704. doi: 10.1200/JCO.2015.65.9789.
［15］	Querfeld C S, Tsai N C, Palmer J, et al. Phase 1 results of anti⁃PD⁃ligand 1 （DURVALUMAB） & lenalidomide in patients with cutaneous T cell lymphoma and correlation with gene expression profile ［J］. Hematological oncology, 2021,39（Suppl 2）:296⁃297.doi:10.1002/hon.2880.
［16］	Bar⁃Sela G, Bergman R. Complete regression of mycosis fungoides after ipilimumab therapy for advanced melanoma［J］. JAAD Case Rep, 2015,1（2）:99⁃100. doi: 10.1016/j.jdcr.2015.02. 009.
［17］	Xiao M, Hennessey D, Iyer A, et al. Transcriptomic changes during stage progression of mycosis fungoides［J］. Br J Dermatol, 2022,186（3）:520⁃531. doi: 10.1111/bjd.20760.
［18］	Herrera A, Cheng A, Mimitou EP, et al. Multimodal single⁃cell analysis of cutaneous T⁃cell lymphoma reveals distinct subclonal tissue⁃dependent signatures［J］. Blood, 2021,138（16）:1456⁃1464. doi: 10.1182/blood.2020009346.
［19］	Horwitz SM, Koch R, Porcu P, et al. Activity of the PI3K⁃δ,γ inhibitor duvelisib in a phase 1 trial and preclinical models of T⁃cell lymphoma［J］. Blood, 2018,131（8）:888⁃898. doi: 10.1182/blood⁃2017⁃08⁃802470.
［20］	Huen A, Haverkos BM, Zain J, et al. Phase I/Ib study of tenalisib （RP6530）, a dual PI3K δ/γ inhibitor in patients with relapsed/refractory T⁃cell lymphoma［J］. Cancers （Basel）, 2020,12（8）doi: 10.3390/cancers12082293.
［21］	Witzig TE, Reeder C, Han JJ, et al. The mTORC1 inhibitor everolimus has antitumor activity in vitro and produces tumor responses in patients with relapsed T⁃cell lymphoma［J］. Blood, 2015,126（3）:328⁃335. doi: 10.1182/blood⁃2015⁃02⁃629543.
［22］	Bresin A, Cristofoletti C, Caprini E, et al. Preclinical evidence for targeting PI3K/mTOR signaling with dual⁃inhibitors as a therapeutic strategy against cutaneous T⁃cell lymphoma［J］. J Invest Dermatol, 2020,140（5）:1045⁃1053.e6. doi: 10.1016/j.jid. 2019.08.454.
［23］	Shi Y, Dong M, Hong X, et al. Results from a multicenter, open⁃label, pivotal phase II study of chidamide in relapsed or refractory peripheral T⁃cell lymphoma［J］. Ann Oncol, 2015,26（8）:1766⁃1771. doi: 10.1093/annonc/mdv237.
［24］	何杏兰, 王艺萌, 王冠钰, 等. 西达本胺联合苦参碱对皮肤T细胞淋巴瘤细胞系增殖、凋亡的影响及可能的凋亡机制［J］. 中华皮肤科杂志, 2020,53（2）:121⁃127. doi: 10.35541/cjd.2019 0906.
［25］	谷晓广, 吴芳妮, 张芊, 等. 西达本胺联合姜黄素对人皮肤T细胞淋巴瘤细胞系Hut78的影响及其分子机制［J］. 中华皮肤科杂志, 2016,49（2）:112⁃118. doi: 10.3760/cma.j.issn.0412⁃4030.2016.02.008.
［26］	Virmani P, Zain J, Rosen ST, et al. Hematopoietic stem cell transplant for mycosis fungoides and Sézary syndrome［J］. Dermatol Clin, 2015,33（4）:807⁃818. doi: 10.1016/j.det.2015.05. 014.
［27］	Iqbal M, Reljic T, Ayala E, et al. Efficacy of allogeneic hematopoietic cell transplantation in cutaneous T cell lymphoma: results of a systematic review and meta⁃analysis［J］. Biol Blood Marrow Transplant, 2020,26（1）:76⁃82. doi: 10.1016/j.bbmt.2019.08.019.
［28］	Kawai H, Ando K, Maruyama D, et al. Phase II study of E7777 in Japanese patients with relapsed/refractory peripheral and cutaneous T⁃cell lymphoma［J］. Cancer Sci, 2021,112（6）:2426⁃2435. doi: 10.1111/cas.14906.

[1]	陈星宇姚煦. 中性粒细胞在炎症性皮肤病中的研究进展[J]. 中华皮肤科杂志, 2024, 0(3): 20220865-e20220865.
[2]	王诗琪王爱平李航李若瑜. 趾甲银屑病与指甲银屑病的皮肤镜特征比较[J]. 中华皮肤科杂志, 2024, 57(2): 161-165.
[3]	中国医师协会皮肤科医师分会中华医学会皮肤性病学分会中国医疗保健国际交流促进会皮肤医学分会疑难重症及罕见病国家重点实验室国家皮肤与免疫疾病临床医学研究中心. 特应性皮炎治疗药物应用管理专家共识（2024版）[J]. 中华皮肤科杂志, 2024, 57(2): 97-108.
[4]	中国“一带一路”皮肤病专病联盟分枝杆菌病研究联盟中国麻风防治协会皮肤性病检验与诊断分会. 中国皮肤非结核分枝杆菌病诊治专家共识（2024版）[J]. 中华皮肤科杂志, 2024, 57(2): 109-118.
[5]	那君李若瑜仲少敏杨莉吴艳. 玫瑰痤疮真实世界诊疗现状调查分析[J]. 中华皮肤科杂志, 2024, 57(2): 127-133.
[6]	郭蕾曹春艳方晓雅冯素英. 自身免疫性大疱病患者创面感染多重耐药菌现况及危险因素分析[J]. 中华皮肤科杂志, 2024, 57(2): 155-160.
[7]	STAR皮肤科学专科委员会. 2022年医学期刊发表中国皮肤病学指南和共识的科学性、透明性和适用性评级[J]. 中华皮肤科杂志, 2024, 57(2): 141-146.
[8]	陈慧李冰李春英郭伟楠. 水刀磨削或电动磨削联合负压吸疱自体表皮移植术治疗白癜风的疗效比较[J]. 中华皮肤科杂志, 2024, 57(1): 43-45.
[9]	陈孝文李婷婷陈文静康晓静. 以单发皮损为首发表现的卡波西肉瘤12例[J]. 中华皮肤科杂志, 2024, 57(1): 39-42.
[10]	闫娜陈婷耿松梅李政霄刘燕马迎新谭宣丰. 皮下非对称减张联合真皮埋没成角褥式缝合在婴幼儿面部良性色素性皮损手术治疗中的应用[J]. 中华皮肤科杂志, 2024, 57(1): 54-57.
[11]	岳超段梦莹王涛章满玉戴叶芹彭建中宋秀祖. 上睑眼轮匝肌岛状皮瓣修复眼睑及眶周皮肤肿瘤切除后继发缺损28例回顾性分析[J]. 中华皮肤科杂志, 2023, 56(9): 862-865.
[12]	戴乐恒胡雯张坤杰康晓静. 异鼠李素对H2O2诱导的HaCaT细胞线粒体结构及功能损伤的保护作用研究[J]. 中华皮肤科杂志, 2023, 56(9): 857-861.
[13]	孙小洁刘毅. 抗雄激素药物治疗皮肤病研究进展[J]. 中华皮肤科杂志, 2023, 56(9): 882-885.
[14]	邵依王雷刘芳. 蕈样肉芽肿伴大细胞转化和原发性皮肤间变性大细胞淋巴瘤临床病理比较分析[J]. 中华皮肤科杂志, 2023, 56(9): 853-857.
[15]	陈春里闫思聿王丹高丽华谭丽娜唐四元刘伟曾金容鲁建云. 酸化脂肪酸酯治疗特应性皮炎样模型小鼠的疗效及机制初探[J]. 中华皮肤科杂志, 2023, 56(9): 822-831.

复发/难治性皮肤T细胞淋巴瘤的非化疗药物新选择

Novel non-chemotherapeutic treatment options for relapsed/refractory cutaneous T-cell lymphomas

PDF

PDF (Mobile)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 28

相关文章 15

Metrics

本文评价

推荐阅读 10